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More than 40 years after Benjamin and colleagues1 reported the benefit of 
doxorubicin in metastatic soft-tissue sarcomas, doxorubicin either as monotherapy or 
in combination with ifosfamide is still the standard first-line treatment in most soft-
tissue sarcomas.2 
In contrast to gastrointestinal stromal tumours in which the introduction of 
multitargeted tyrosine kinase inhibitors that target KIT or platelet-derived growth 
factor receptor (PDGFR) mutated tumours have led to an impressive improvement in 
survival, this success has not been achieved in non-gastrointestinal stromal tumour 
soft-tissue sarcomas. The development of novel systemic treatments in soft-tissue 
sarcomas is challenging: there are more than 70 different histological subtypes, with 
heterogeneous genetic make-up and clinical behaviour including age at diagnosis 
and disease aggressiveness.3,4;5 Data show differences between subtypes of soft-
tissue sarcomas in overall survival, measured from the start of the first systemic 
treatment for advanced disease, from 9·3 months in undifferentiated pleiomorphic 
sarcoma to 24·4 months in leiomyosarcomas.6 
William Tap and colleagues7 report in The Lancet an open-label phase 1b and 
randomised phase 2 trial of olaratumab and doxorubicin versus doxorubicin alone in 
unresectable and metastatic soft-tissue sarcomas. Olaratumab is a human 
immunoglobulin G subclass 1 (IgG1) monoclonal antibody that binds to PDGFRα 
and blocks the PDGF-AA, PDGF-BB, and PDGF-CC ligands from binding to the 
receptor. Adult patients with locally advanced or metastatic soft-tissue sarcomas, 
anthracycline naive with performance status of 0–2, and availability of tumour 
material were eligible. The primary endpoint of the phase 2 study was progression-
free survival (PFS); overall survival, response rate, and safety were secondary 
endpoints. Patients were either randomly assigned to a maximum of eight courses of 
75 mg/m2 doxorubicin on day 1 with 15 mg/kg olaratumab on days 1 and 8 with the 
option to continue with the antibody alone until disease progression, or to 
doxorubicin, in which patients with disease progression could be treated with 
olaratumab. 
The results of 133 patients in the intention-to-treat analysis, 66 in the combination 
group and 67 in the doxorubicin group, showed a gain in median PFS of 6·6 months 
(95% CI 4·1–8·3, IQR 2·7–10·2) versus 4·1 months (2·8–5·4, 1·6–7·4), a significant 
median overall survival gain in the combination group of 26·5 months (20·9–31·7, 
13·8 to not assessable) versus 14·7 months (9·2–17·1, 5·5–26·0), a hazard ratio 
(HR) of 0·46 (95% CI 0·30–0·71), but no difference in objective response rate, which 
was 18·2% (9·8–29·6) versus 11·9% (5·3–22·2). The median number of doxorubicin 
courses in the combination group versus the single agent doxorubicin group was 
seven and four, the response duration was 8·3 versus 8·2 months, respectively. Of 
the 129 patients who started their assigned treatment, 38 (59%) of 64 patients in the 
olaratumab plus doxorubicin group versus 44 (68%) of 65 patients in the doxorubicin 
group died from disease, and no patients versus six (9%) patients died from adverse 
events, respectively. The HR for overall survival was 0·38 (95% CI 0·21–0·68) in 
those with a disease duration of less than 14·95 months and was 0·68 (0·37–1·25) in 
those with disease equal to or longer than 14·95 months. In terms of adverse events, 
neutropenia, mucositis, nausea, vomiting, and diarrhoea were more frequent in the 
olaratumab and doxorubicin group than in the doxorubicin alone group. Febrile 
neutropenia of grade 3 or greater was similar in both groups. 
It is not the first study targeting PDGFR in non-gastrointestinal stromal tumour soft-
tissue sarcomas. Pazopanib, a multitargeted tyrosine kinase inhibitor targeting 
VEGFR 1, 2, 3 and PDGFRα and PDGFRβ was first tested in soft-tissue sarcomas 
in a multistrata EORTC phase 2 study.8 In the subsequent phase 3 PALETTE study,9 
patients with metastatic non-adipocytic soft-tissue sarcomas were randomly 
assigned to either pazopanib or placebo after first-line treatment, provided they had 
progression according to Response Evaluation Criteria In Solid Tumors (version 1.1). 
This study showed a significant median PFS advantage of 3 months and a non-
significant gain in median overall survival of 1·8 months.9 Remarkably, pazopanib 
was introduced as an angiogenesis inhibitor because of its activity in clear cell renal 
cancer, but it cannot be excluded that its mode of action in soft-tissue sarcomas at 
least partly encompasses targeting PDGFR. 
In Tap and colleagues' study, the difference in overall survival of almost a year, 
which is far beyond the gain in PFS of 2·5 months, is as much promising as puzzling. 
Histologies seem to be reasonably balanced between the groups, with 
leiomyosarcomas as the largest group. The exact effect of various post-study 
treatments, including local treatments, is not easy to interpret. Differences in the 
pace of progression before start of treatment might have affected the results 
because no specific time period in which progression should have occurred before 
patients entered the study was defined and only the group with shorter history of 
disease showed a significant increase in overall survival. The double-blind, phase 3 
ANNOUNCE study (NCT02451943) with doxorubicin plus olaratumab or placebo, 
which is currently recruiting, has overall survival as the primary endpoint and 
because of the higher number of patients, the result will be more powerful than Tap 
and colleagues' study. Although more toxicity was noted in the combination group, 
treatment-related deaths were confined to the doxorubicin group. The maximum 
number of eight courses of doxorubicin, 600 mg doxorubicin/m2 cumulative, is 
unusual and is above the general dosage that is deemed safe of 450–500 mg/m2, 
which raises concern10 and given the context of the study population long-term 
follow-up data are absent. The consequential necessity to add the cardioprotective 
dexrazoxane noticeably increases the total costs of this treatment. 
Finally, why does targeting PDGFRα and its combination with doxorubicin lead to 
this impressive gain in overall survival? In-depth knowledge about PDGFR receptors, 
the relevance of their presence in tumour and stroma, their ligands, and signalling 
pathways is still relatively scarce in sarcomas.11,12 For successful antibody treatment, 
the presence of accessible membranous receptors and affinity of the antibody to the 
receptors are key factors and these will probably be different between soft-tissue 
sarcoma subtypes. The evaluation of PDGFRα expression as was done in Tap and 
colleagues' study showed difficulties in standardisation, which have to be solved, but 
most probably finding a predictive biomarker will be much more complex and 
potentially not be universal across all soft-tissue sarcomas. 
In view of the desperate need of patients with soft-tissue sarcomas for new active 
drugs, the findings of Tap and colleagues are promising but need confirmation in a 
larger study. The results of ANNOUNCE are eagerly awaited, alongside a better 
understanding of the mode of action of olaratumab and a biomarker related to 
PDGFRα for optimum patient selection. 
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